What Does Halozyme Do?
Founded in 1998 and headquartered in San Diego, Halozyme has built its entire business around one patented enzyme technology: rHuPH20, a recombinant human hyaluronidase. Its ENHANZE® platform uses this enzyme to enable subcutaneous (under-the-skin) delivery of drugs that previously required intravenous infusion — meaning patients can receive treatments in minutes at home instead of hours at a clinic. Halozyme doesn't make drugs itself; it licenses ENHANZE to 20+ major pharma companies including Roche, Janssen (J&J), Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, and argenx. In return, it earns royalties on every dose sold.
Halozyme's genius is the tollbooth model — it owns the road, and every major drug company has to pay to use it.
— Easy EquityBQ Score — Business Quality
Financial Performance
Halozyme has grown strongly across all metrics. Royalty revenue — the highest-quality, highest-margin revenue line — now comprises 63–67% of total revenue and is growing at 40–64% year-on-year. Operating margins have expanded from 54% (FY2024) to 62% by mid-2025. Full-year 2025 guidance has been raised twice — total revenue now guided at $1.30–1.375B.
| Period | Rev Growth | Royalty % | Op Margin | Net Margin |
|---|
| FY 2024 | +22% | 56% | 54% | 44% |
| Q1 2025 | +35% | 64% | 53% | 44% |
| Q2 2025 | +41% | 63% | 62% | 51% |
| Q3 2025 | +22% | 67% | 62% | 49% |
Exceptional Capital Efficiency
ROA 27.45%, ROE 124.5%, ROIC 45.67% — placing Halozyme in the top 10 of 622 companies screened on return metrics. The royalty model requires almost no incremental capital to grow, which is why returns are so high even as debt has increased.
Key Risks
Risk 1 — ENHANZE Patent Expiry
US composition patents expire in September 2027. European patents validated in 37 countries expire in March 2029. After these dates, the core ENHANZE competitive moat weakens significantly. Long-term growth beyond 2029 is genuinely uncertain.
Risk 2 — Zero Pricing Power
Halozyme earns royalties on its partners' drug sales. If the Inflation Reduction Act (IRA) drug pricing negotiations compress prices on ENHANZE-enabled drugs — like Darzalex (daratumumab) — Halozyme's royalty income falls with no ability to offset it. A CMS draft guidance in May 2025 caused a ~16% single-day stock drop on exactly this concern.
Risk 3 — Revenue Concentration
60% of accounts receivable comes from just Janssen and Roche. High dependence on a small number of large partners creates vulnerability if any licensing agreement changes or if a key drug faces competitive pressure.
Upcoming Catalyst — Elektrofi Acquisition
Halozyme's planned acquisition of Elektrofi (Hypercon technology) could open a new platform for ultra-high-concentration drug delivery. Royalty contributions are projected to begin in 2030, which could help bridge the post-ENHANZE patent period.
Analyst View
9 analysts cover HALO — 6 Buy, 3 Hold. Price targets range from $56 to $92, averaging $76 against a current price of $68.95. Forward P/E of 8.28× is anomalously low for a high-margin royalty business, reflecting the market's concern about post-2029 growth. The PEG of 0.26 implies the market is deeply undervaluing growth relative to earnings trajectory.
Easy Equity Verdict
A high-quality royalty engine — but the clock is ticking on the core patent.
Halozyme is operationally excellent: high margins, high returns, and a growing royalty stream from blockbuster drugs. The problem is structural — ENHANZE patents expire 2027–2029, and the company has limited pricing power given its dependency on partner drug pricing. A post-FY2025 dip could offer a good entry for shorter-term investors, but long-term conviction requires evidence that Elektrofi or other new platforms can replace ENHANZE revenue after 2029. Watch but don't rush.